Clara Ramos Belinchón, Helena Martínez-Lozano, Clara Serrano Moreno, Diego Hernández Castillo, Pablo Lois Chicharro, Pablo Ferreira Ocampo, Ignacio Marín-Jiménez, Irene Bretón Lesmes, Luis Menchén
BACKGROUND: Obesity affects many patients with inflammatory bowel disease (IBD). Glucagon-like peptide (GLP)-1 agonists are a promising therapy for obese patients. However, there is a lack of evidence of the use of these drugs in IBD populations. We investigated the efficacy and safety of GLP-1 agonists in a cohort of obese patients with IBD. METHODS: We analyzed a cohort of consecutive IBD patients who received GLP-1 agonists indicated for treating obesity between 2019 and 2021...
May 20, 2024: Revista Española de Enfermedades Digestivas
Kazuki Santa, Tomonori Ohsawa
BACKGROUND: Recently, the number of patients who manifest intestinal disorders has increased. Particularly, Irritable Bowel Syndrome (IBS) patients and Inflammatory Bowel Disease (IBD) patients, which include Ulcerative Colitis (UC) and Crohn's Disease (CD), are on the rise, especially in the young generation. Behcet's disease (an autoimmune disease) and bowel obstruction are also common intestinal disorders. Furthermore, colorectal cancer, including colon and rectum cancer and small intestinal cancer, are the typical disorders in the intestine...
May 17, 2024: Endocrine, Metabolic & Immune Disorders Drug Targets
Qi Zhu, Yunfeng Fu, Jianhao Qiu, Langyi Guan, Foqiang Liao, Yawei Xing, Xiaodong Zhou
BACKGROUND: Several studies indicated that inflammatory bowel disease (IBD) may contribute to increased susceptibility to primary biliary cholangitis (PBC). However, the causal relationship between IBD and PBC remains unclear. METHODS: The genetic variant data of patients with IBD and PBC were obtained from published genome-wide association studies (GWASs). The IBD data were further divided into a discovery dataset and a validation dataset depending on the data source...
2024: Gastroenterology Report
Osama Jabi, Nan Lan, Akshay Pokala, Ravi P Kiran, Bo Shen
BACKGROUND: Strictures are a common complication after ileal pouch surgery with the most common locations being at the anastomosis, pouch inlet, and stoma closure site. No previous literature has described endoscopic therapy of stoma site stricture. This study aimed to assess the safety and efficacy of endoscopic therapy in the treatment of stoma closure site strictures. METHOD: Patients diagnosed with stoma closure site strictures following ileal pouch surgery who underwent endoscopic treatment at the Center for Colorectal Diseases, Inflammatory Bowel Disease (IBD), and Ileal Pouch between 2018 and 2022 were analysed...
2024: Gastroenterology Report
Fabiana Zingone, Alessandro Borsato, Daria Maniero, Francesco Della Loggia, Greta Lorenzon, Annalisa Zanini, Cristina Canova, Brigida Barberio, Edoardo Vincenzo Savarino
BACKGROUND: Inflammatory bowel diseases (IBDs) have a peak incidence between the second and fourth decades of life and can affect women's reproductive life. OBJECTIVES: Our study aimed to assess the impact of IBD on the reproductive life of female patients with this condition. DESIGN: Cross-sectional study. METHODS: Women with IBD followed at our IBD Unit and a group of healthy controls were enrolled. Data on reproductive life were collected using a dedicated questionnaire...
2024: Therapeutic Advances in Gastroenterology
Nesa Kazemifard, Maryam Farmani, Shaghayegh Baradaran Ghavami, Mohammad Kazemi, Shabnam Shahrokh, Hamid Asadzadeh Aghdaei, Mohammadreza Zali
Long non-coding RNAs (lncRNAs) regulate multiple pathways and cellular mechanisms. Recent research has emphasized their involvement in the pathogenesis of complex diseases, such as Inflammatory Bowel Disease (IBD) which is characterized by chronic inflammation of the intestines. The two most common types of IBD are ulcerative colitis and Crohn's disease. CRNDE lncRNA was initially detected in colorectal cancer (CRC) and found to be involved in the tumorigenesis pathways. Further studies revealed the role of CRNDE in activating inflammation and promoting the release of inflammatory cytokines...
July 2024: Biochemistry and Biophysics Reports
Margo M Szabo, Cecelia I Nelson, Christa L Lilly, Ellen M Manegold, Brian D Riedel, Audra S Rouster, Christina L Duncan
OBJECTIVE: Youth with inflammatory bowel disease (IBD) may be at increased risk for sleep difficulties due to the painful and inflammatory nature of their disease. Moreover, children and adolescents with IBD experience impairment across a variety of psychosocial domains. However, researchers have yet to investigate the complex interplay between sleep, disease-related symptoms, and psychosocial factors in this population. The purpose of this study was to examine sleep patterns, pain, and mood in pediatric IBD...
March 2024: Clinical Practice in Pediatric Psychology
Lichen Tang, Zheng Lin
BACKGROUND: Stigma is assumed to lead to negative illness identity in one who got chronic illness, and there is a lack of understanding regarding the underly mechanisms. However, no research has examined the extent to which stigma was associated with illness identity in people with IBD. Therefore, we investigated the relationship between stigma and illness identity, specifically to examine whether resilience mediated or moderated the relationship. METHODS: A cross-sectional study was performed among patients diagnosed with inflammatory bowel disease from three tertiary hospitals in Jiangsu Province, China...
2024: Psychology Research and Behavior Management
Poonam Bagai, Pooja Sharma, Aala Ansari, Nirbhay Singh, Sonal Sharma, Padam Singh, Durga Chougule, Manish Kumar Singh, Gargi Singh, Sanjeev Singh
Background Clinical research presents a promising path for improving healthcare in contemporary India. Yet, researchers identify gaps in trust, awareness, as well as misconceptions about being a '"guinea pig." We proposed building the capacity of training patient advocacy groups (PAGs) in patient-centered clinical research and through them creating aware patients as research partners. Methodology Patient Advocates for Clinical Research (PACER) is a tiered program to share information and education about clinical research with PAGs...
April 2024: Curēus
Ali Khalessi, Brooks R Crowe, Yuhe Xia, Gregory Rubinfeld, Jessica Baylor, Arielle Radin, Peter S Liang, Lea Ann Chen
BACKGROUND AND AIMS: The prevalence of inflammatory bowel disease (IBD) is increasing globally. In this context, identifying risk factors for severe disease is important. We examined how race/ethnicity and immigration status influence IBD manifestations, treatments, and outcomes in a diverse, tertiary-care safety-net hospital. METHODS: We conducted a single-center retrospective review of all IBD inpatients and outpatients treated from 1997-2017. Using logistic regression modeling, we compared disease onset, treatment, and outcomes by race (White, Black, Hispanic, or Asian) and immigration status (US-born vs foreign-born)...
2024: Gastro Hep Adv
Abdullah Alotaibi, Abrar Alhubayshi, Abed Allehibi, Abdullah Almtawa, Nawaf Alotaibi, Adel Alghamdi, Saad Alrajhi, Adel Alqutub, Ahmad Aleid, Abdulrhman Alamr, Bashaar Ibrahim, Mohammed Alahmari, Hussam Alhamidi, Shameem Ahmad, Hadeel AlBayyat, Osama Alshaya, Youssef Altannir, Ahmed Alghamdi
BACKGROUND: Patients with inflammatory bowel disease (IBD) may also experience extraintestinal manifestations (EIMs), which can affect various organ systems, and their occurrence is based on disease activity. OBJECTIVES: To determine the prevalence of EIMs and their most common types among IBD patients from Saudi Arabia. MATERIALS AND METHODS: This retrospective study included all IBD patients aged 14-80 years who visited the Gastroenterology and Hepatology clinics at King Fahad Medical City, Riyadh, between February 2017 and December 2022...
2024: Saudi Journal of Medicine & Medical Sciences
Nikola Mitrev, Viraj Kariyawasam
A treat-to-target strategy in inflammatory bowel disease (IBD) involves treatment intensification in order to achieve a pre-determined endpoint. Such uniform and tight disease control has been demonstrated to improve clinical outcomes compared to treatment driven by a clinician's subjective assessment of symptoms. However, choice of treatment endpoints remains a challenge in management of IBD via a treat-to-target strategy. The treatment endpoints for ulcerative colitis (UC), recommended by the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) consensus have changed somewhat over time...
May 5, 2024: World Journal of Gastrointestinal Pharmacology and Therapeutics
Xiping Liao, Ji Liu, Xiaolong Guo, Ruiping Meng, Wei Zhang, Jianyun Zhou, Xia Xie, Hongli Zhou
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic disease resulting from the interaction of various factors such as social elements, autoimmunity, genetics, and gut microbiota. Alarmingly, recent epidemiological data points to a surging incidence of IBD, underscoring an urgent imperative: to delineate the intricate mechanisms driving its onset. Such insights are paramount, not only for enhancing our comprehension of IBD pathogenesis but also for refining diagnostic and therapeutic paradigms...
2024: Journal of Inflammation Research
Xiaohang Chen, Lianghang He, Chaochao Zhang, Genggeng Zheng, Shuoqi Lin, Yuchun Zou, Youguang Lu, Yan Feng, Dali Zheng
Symbiotic microbial communities are crucial for human health, and dysbiosis is associated with various diseases. Plant-derived nanovesicles (PDNVs) have a lipid bilayer structure and contain lipids, metabolites, proteins, and RNA. They offer unique advantages in regulating microbial community homeostasis and treating diseases related to dysbiosis compared to traditional drugs. On the one hand, lipids on PDNVs serve as the primary substances that mediate specific recognition and uptake by bacteria. On the other hand, due to the multifactorial nature of PDNVs, they have the potential to enhance growth and survival of beneficial bacterial while simultaneously reducing the pathogenicity of harmful bacteria...
May 19, 2024: Journal of Nanobiotechnology
N N Dai, J Li, X Y Shi, W X Dong, Y J Gao, W W Zhu, S Wang, X Y Li, J B Sun, J Zhang, Z L Li
No abstract text is available yet for this article.
May 15, 2024: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
J J Jiang, M S Ma, M Wei, Z Q Qiu
Objective: To investigate the safety, efficacy and effective dose of empagliflozin in the treatment of glycogen storage disease type Ⅰb (GSD Ⅰb). Method: This was a cross sectional study. A total of 28 children with GSDⅠb who started oral empagliflozin treatment from January 2021 to June 2023 in the WeChat group of patients with glycogen storage disease were selected as the study objects. Clinical data such as general situation, current situation of medication and adverse reactions of the children were collected through questionnaires from June 18 to 30, 2023...
May 15, 2024: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
Michael K Yoon, Jonathan E Lu
PURPOSE: The initial management of patients presenting with orbital inflammatory syndromes (OIS) varies - with some pursuing a diagnostic workup while others treat without any testing. The evidence behind this rationale is limited. A review of patients with orbital inflammation is performed with analysis of diagnostic testing to develop a workflow for such patients. DESIGN: A retrospective review of patients presenting with acute orbital inflammation at a single institution from 2011 - 2020 was conducted...
May 17, 2024: American Journal of Ophthalmology
Jiamin Wang, Naiqi Yao, Yonghu Chen, Xuezheng Li, Zhe Jiang
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signal has drawn much consideration due to its sensitivity to DNA in innate immune mechanisms. Activation of the cGAS-STIN signaling pathway induces the production of interferon and inflammatory cytokines, resulting in immune responses, or inflammatory diseases. The intestinal tract is a vital organ for the body's nutrition absorption, recent studies have had various points of view on the job of cGAS-STING pathway in various intestinal sicknesses...
May 18, 2024: International Immunopharmacology
Xiaoxiao Fan, Qiuxia Lu, Qing Jia, Liangqiong Li, Cong Cao, Ziniu Wu, Min Liao
Inflammatory bowel disease (IBD) is a chronic and recurrent gastrointestinal inflammation regulated by intricate mechanisms. Recently, prebiotics is considered as promising nutritional strategy for the prevention and treatment of IBD. Prevotella histicola (P. histicola), an emerging probiotic, possesses apparently anti-inflammatory bioactivity. However, the role and underlying mechanism of P. histicola on IBD remain unclear. Hence, we probe into the effect of P. histicola on dextran sulfate sodium (DSS)-induced colitis and clarified the potential mechanism...
May 18, 2024: International Immunopharmacology
Summer N Meyer, Bridget Myers, Leah Antoinette Caro-Chang, Danielle M Tartar, Peggy Wu, Maija Kiuru, Atrin Toussi
Tumor necrosis factor (TNF) inhibitors may paradoxically induce pustular eruptions, most of which are classified as pustular psoriasis. Amicrobial pustulosis of the folds (APF) is a much rarer entity that was recently recognized to occur in the setting of chronic anti-TNF therapy and inflammatory bowel disease, with 12 existing cases in the literature. Amicrobial pustulosis of the folds is a neutrophilic dermatosis characterized by aseptic pustules involving the major and minor skin folds, genital regions, and scalp...
March 15, 2024: Dermatology Online Journal
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.